Şevket Tolga Tombul

Assoc. Prof. Şevket Tolga Tombul is an accomplished medical professional and academic with a focus on pharmaceutical research and development. He completed his doctoral studies in 2020 at Erciyes University, Institute of Health Sciences, specializing in Pharmaceutical Research and Development Applications. Building on his academic credentials, he has continued his clinical and professional work with Acibadem Health Group since 2022. His combined experience in medicine, research, and applied pharmaceutical sciences informs his teaching, clinical practice, and contributions to healthcare innovation.

Education

• 2020 Erciyes University, Institute of Health Sciences / Pharmaceutical Research and Development Application / PhD
• 2009 Hacettepe University Faculty of Medicine Urology
• 2003 Hacettepe University Faculty of Medicine

Experience

• 2022 Acibadem Health Group

Publications

• Superselective vesical artery embolization versus intravesical formalin for intractable hematuria in patients with bladder cancer.
  Actas urologicas espanolas, 2021 (SCI Expanded Indexed Journal) Sonmez G., Tolga Tombul Ş. T. , Herdem N., Demirtas T., Tatlısen A., Demirtas A.
• RE: SHEN ET AL: TARGETED BIOPSY WITH REDUCED NUM^R OF CORES: OPTIMAL SAMPLING SCHEME IN PATIENTS UNDERGOING MAGNETIC RESONANCE IMAGING /TRANSRECTAL ULTRASOUND FUSION PROSTATE BIOPSY
  ULTRASOUND IN MEDICINE AND BIOLOGY, vol.47, sa.3, pp.847, 2021 (SCI Indexed Journal) SÖNMEZ G., TOMBUL Ş. T. , DEMİRTAŞ T., DEMİRTAŞ A.
• Diagnostic efficiency of systemic immune-inflammation index in fusion prostate biopsy
  ACTAS UROLOGICAS ESPANOLAS, vol.45, sa.5, pp.359-365, 2021 (SCI Indexed Journal) Sonmez G., Demirtas T., Tombul S. T. , Akgun H., Demirtas A.
• Clinical factors for predicting malignancy in patients with PSA < 10 ng/mL and PI-RADS 3 lesions
  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020 (SCI Indexed Journal) SÖNMEZ G., TOMBUL Ş. T. , DEMİRTAŞ T., DEMİRTAŞ A.
• Comparison of pain levels in fusion prostate biopsy and standard TRUS-guided biopsy
  INTERNATIONAL BRAZ J UROL, vol.46, sa.4, pp.557-562, 2020 (SCI Indexed Journal) Demirtas A., Sonmez G., Tombul S. T. , Demirtas T.
• Risk factors associated with pain in fusion prostate biopsy
  PROSTATE INTERNATIONAL, vol.8, pp.185-189, 2020 (SCI Indexed Journal) SÖNMEZ G., TOMBUL Ş. T. , DEMİRTAŞ T., DEMİRTAŞ A.
• What is the ideal number of biopsy cores per lesion in targeted prostate biopsy?
  PROSTATE INTERNATIONAL, 2020 (SCI Indexed Journal) SÖNMEZ G., DEMİRTAŞ T., TOMBUL Ş. T., ÖZTÜRK F., DEMİRTAŞ A.
• Two-step treatment model for the adult patients with an obstructed kidney functioning below 10% of its capacity: a pilot study
  CLINICAL AND EXPERIMENTAL NEPHROLOGY, vol.24, sa.2, pp.185-189, 2020 (SCI Indexed Journal) Demirtaş A., Güleser A., Sönmez G., Demirtaş T., Tombul Ş. T.
• X. Comparison of the Upgrading Rates of International Society of Urological Pathology Grades and Tumor Laterality in Patients Undergoing Standard 12-Core Prostate Biopsy versus Fusion Prostate Biopsy for Prostate Cancer.
  Urologia internationalis, vol.103, pp.256-261, 2019 (SCI Expanded Indexed Journal) Demirtaş A., Sönmez G., Tombul Ş. T. , Demirtaş T., Akgün H.
• IX. A Single-center Experience: Does MRI-guided Target Prostate Biopsy Meet Expectations?
  Cureus, vol.11, sa.11, 2019 (SCI Expanded Indexed Journal) DEMİRTAŞ T., Sonmez G., Tombul Ş. T. , DEMİRTAŞ A.